Football Star Cooper Kupp Encourages Eye Allergy Sufferers to Find the Right Tool for the Job with Pataday
06 Juni 2022 - 02:00PM
Business Wire
- Fresh campaign highlights Cooper Kupp’s experience with eye
allergies and how Pataday can provide itch relief for millions of
Americans with eye allergies1
- Partnership supports Pataday Once Daily Relief Extra Strength,
the first 24-hour eye allergy itch relief drop available without a
prescription in the U.S.2
- Multimedia program motivates consumers to add Pataday eye
allergy drops to their allergy routine for targeted eye itch
relief
Alcon, the global leader in eye care dedicated to helping people
see brilliantly, today announced a partnership with Cooper Kupp,
professional football wide receiver and MVP of the “Big Game,” to
share his experience with eye allergies and help other eye allergy
sufferers find relief with Pataday® Once Daily Relief Extra
Strength. This year’s campaign, The Right Tool for the Job,
highlights Kupp’s personal struggle to find the right product to
treat his eye allergy symptoms and how Pataday has delivered
fast-acting, long-lasting, and targeted relief for his itchy
allergy eyes on and off the field.
“When the seasons change, which, unfortunately, coincides with
spring organized team activities (OTAs) and the dog days of
training camp, my allergies flare up. In those weeks, when we’re
outdoors working out, the pollen can really make my eyes itch and
distract me from focusing on the small but crucial details of my
work,” said Kupp. “I use Pataday Once Daily Relief Extra Strength
because it puts me in control of my allergy symptoms and it’s
efficient. With just one drop in each eye, I love that I can count
on 24 hours of relief from itchy eyes.”
Pataday is the #1 doctor-recommended eye allergy itch relief
drop brand and is available without a prescription.3 As an
antihistamine eye drop, the product works right on the cells that
make your eyes itch.2 To highlight key product benefits and
encourage consumers to consider Pataday as The Right Tool for the
Job of treating itchy allergy eyes, a full-scale media campaign
will run in 2022, including organic and paid social content;
partnerships with social media influencers detailing their
experiences with eye allergies; and a drive for consumers to learn
more about and try Pataday Once Daily Relief Extra Strength.
“Alcon is thrilled to welcome Cooper Kupp to the Pataday team as
a consumer advocate for an important, but often overlooked, allergy
patient need,” said Harvey Brown Jr., Senior Director, Dry Eye and
Ocular Health at Alcon. “Approximately 66 million Americans suffer
from ocular allergies, but only 9 million use an over-the-counter
allergy eye drop to relieve their symptoms.4-7 Through this
campaign, we hope to encourage eye allergy sufferers to find
targeted, fast-acting relief from their eye allergy symptoms.”
Pataday Once Daily Relief Extra Strength is available in the
U.S. in drug, mass and grocery stores, as well as online retailers.
Alcon’s Pataday portfolio of products offers fast, long-lasting eye
allergy itch relief to the U.S. population affected by allergic
conjunctivitis.2 Pataday Once Daily Relief Extra Strength provides
a full 24 hours of eye allergy itch relief from pollen, ragweed,
grass, and animal hair and dander for people ages two and older
with just one drop once a day.2
For more information, visit Pataday.com.
Cautionary Note Regarding
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: “anticipate,”
“intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,”
“seek,” “believe,” “project,” “estimate,” “expect,” “strategy,”
“future,” “likely,” “may,” “should,” “will” and similar references
to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties and risks that
are difficult to predict. Some of these factors are discussed in
our filings with the United States Securities and Exchange
Commission, including our Form 20-F. In particular, our
expectations could be affected by uncertainties regarding the
success of our separation and spin-off from Novartis. Should one or
more of these uncertainties or risks materialize, or should
underlying assumptions prove incorrect, actual results may vary
materially from those anticipated. Therefore, you should not rely
on any of these forward-looking statements.
Forward-looking statements in this press release speak only as
of the date of its filing, and we assume no obligation to update
forward-looking statements as a result of new information, future
events or otherwise.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye
care with a heritage spanning over 75 years, we offer the broadest
portfolio of products to enhance sight and improve people’s lives.
Our Surgical and Vision Care products touch the lives of more than
260 million people in over 140 countries each year living with
conditions like cataracts, glaucoma, retinal diseases and
refractive errors. Our more than 24,000 associates are enhancing
the quality of life through innovative products, partnerships with
Eye Care Professionals and programs that advance access to quality
eye care. Learn more at www.alcon.com.
References
- U.S. Census Bureau. 2019.
- PAZEO® [package insert]. Fort Worth, TX: Alcon Laboratories,
Inc; 2016.
- Based on IQVIA ProVoice Survey of Physicians and Optometrists
12 months ending December 31, 2021.
- U.S. Census Bureau (2014). US CENSUS BUREAU - Projections of
the Population by Sex and Age for the United States - 2015 to
2060.
- Singh, K, Axelrod S, Bielory L. The epidemiology of ocular and
nasal allergy in the United States, 1988-1994.
- U.S. Population Census 2019. 6. Nielsen Household Panel Data
Feb. 2019.
- Nielsen Latest 52 weeks 2/6/2019.
Connect with us on Facebook LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220605005103/en/
Media Relations Wes Warnock
+ 41 589 112 111 (Geneva) + 1 817 615 2501 (Fort
Worth) globalmedia.relations@alcon.com Investor Relations Allen Trang + 41 589
112 110 (Geneva) + 1 817 615 2789 (Fort Worth)
investor.relations@alcon.com
Alcon (NYSE:ALC)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Alcon (NYSE:ALC)
Historical Stock Chart
Von Mär 2023 bis Mär 2024